Cancer Sci News Today

 Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur...

TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...

Company Announcement TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma ...

Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Jul 21, 2023--

/PRNewswire/ -- In a study recently published in Cancer Science, researchers from Kanazawa University show how some intestinal cancer cells lose their ability...

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell...

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational...